

1 **Promoting Smoking Cessation and Preventing Relapse to Tobacco Use following a smokefree**
2 **mental health in-patient stay (SCEPTRE feasibility study): a multi-centre randomised controlled**
3 **feasibility study protocol.**

4

5 Petal Petersen Williams* (1,2,3), Lisa Huddleston (1), Emily Shoemith (1), Samantha Brady (4), Alex
6 Mitchell (4), Victoria Exley (4), Fraser Wiggins (4), Lesley Sinclair (4), Jodi Pervin (1), Michelle
7 Horspool (5), Moira Leahy (5), Claire Paul (6), Lesley Colley (7), Lion Shahab (8), Jude Watson (4),
8 Catherine Hewitt (4), Simon Hough (9), John Britton (10), Tim Coleman (11), Simon Gilbody (1, 12),
9 Steve Parrott (1), Paul Galdas (1), Gregor Russell (13), Peter Coventry (1,14), Elena Ratschen (1)

10

- 11 1. Mental Health and Addiction Research Group, Department of Health Sciences, University of
12 York, UK
13 2. Mental Health, Alcohol, Substance Use and Tobacco Research Unit, South African Medical
14 Research Council, South Africa
15 3. Institute for Life Course Health Research, Department of Global Health, Stellenbosch
16 University, South Africa
17 4. York Trials Unit, University of York, UK
18 5. Research and Development, Sheffield Health and Social Care NHS Foundation Trust,
19 Sheffield, UK
20 6. Research and Development, Leeds and York Partnership NHS Foundation Trust, Leeds, UK
21 7. Research and Development, Tees, Esk and Wear Valleys NHS Foundation Trust, Stockton on
22 Tees, UK
23 8. Department of Behavioural Science and Health, University College London, London, UK
24 9. Independent PPI Co-applicant, Cheshire, UK
25 10. University of Nottingham, UK
26 11. Centre for Academic Primary Care, University of Nottingham, Nottingham, UK
27 12. Hull York Medical School, University of York, York, UK
28 13. Research and Development, Bradford District Care NHS Foundation Trust, Bradford, UK
29 14. York Environmental Sustainability Institute, University of York, York, UK

30

31

32

33

34

35

36 *Corresponding author: Petal Petersen Williams, PhD, Mental Health and Addiction Research Group, Department of Health
37 Sciences, University of York, Heslington, York YO10 5DD, UK. *E-mail address:* petal.petersenwilliams@york.ac.uk *Tel:* +44
38 (0)1904 32 4923

39

40 **Keywords: Tobacco, smoking, mental illness, feasibility, smoking cessation, intervention**

41 **Words: 4872**

42 **ABSTRACT**

43 **Introduction**

44 Thousands of patients with mental illness are admitted to acute adult mental health wards every
45 year in England, where local guidance recommends that all mental health settings be entirely
46 smokefree. Mental health trusts presently invest substantial effort and resources to implement
47 smokefree policies and to deliver tobacco dependence treatment to patients. Providing adequate
48 support can help smokers remain abstinent or quit smoking during their smokefree inpatient stay
49 and beyond. At present, little is known about how best to support patients to prevent their return to
50 pre-admission smoking behaviours after discharge from a smokefree mental health inpatient stay.
51 We have developed an intervention which includes targeted resources to support smoking-related
52 behaviour change in patients following discharge from a smoke-free mental health setting. The aim
53 of this trial is to determine the feasibility of a large-scale clinical trial to test the effectiveness and
54 cost-effectiveness of the SCEPTRE intervention, compared with usual care.

55 **Methods and Analysis**

56 This feasibility study will be an individually randomised, controlled trial in eight National Health
57 Service (NHS) mental health trusts recruiting adults (≥ 18 years) admitted to an acute adult mental
58 health inpatient setting who are tobacco smokers on admission, or at any point during their inpatient
59 stay. Consenting participants will be randomised to receive a 12-week intervention consisting of
60 components aimed at promoting or maintaining positive smoking-related behaviour change
61 following discharge from a smoke-free mental health inpatient setting or usual care. Data will be
62 collected at baseline, 3-months and a second timepoint between 4-6 months post-randomisation.
63 With 64 participants (32 in each group) the trial will allow a participation rate of 15% and completion
64 rate of 80% to be estimated within a 95% confidence interval of $\pm 3\%$ and $\pm 10\%$ respectively. The
65 analysis will be descriptive and follow a prespecified plan.

66 **Ethics and Dissemination**

67 Ethics approval was obtained from the North West - Greater Manchester West Research Ethics
68 Committee. We will share results widely through local, national and international academic, clinical
69 and Patient and Public Involvement (PPI) networks. The results will be disseminated through
70 conference presentations, peer-reviewed journals and will be published on the trial website:
71 <https://sceptresearch.com/>.

72 **Trial registration number:** ISRCTN77855199

73

74

75

76 **Strengths and limitations of this study**

77

- 78 • The use of a theory and evidence-based intervention to support smoking cessation and
79 prevent relapse to tobacco following a smokefree mental health inpatient stay, can be
80 effective for impacting long term smoking behaviour.
- 81 • The objective of the SCEPTRE feasibility trial is to test recruitment and randomisation of
82 participants and collection of proposed outcome data in planning for a large randomised
83 controlled trial.
- 84 • Quantitative and qualitative methods will be used to determine if research and intervention
85 processes are acceptable and feasible and inform the decision of progression to full trial.
- 86 • The outcomes to be assessed will be relevant to patients, carers, mental health professionals,
87 and policymakers.
- 88 • The present study is limited to English speaking adults admitted to acute mental health
89 inpatient wards.
- 90 • Usual care varies greatly within and between Trusts nationally, making comparisons between
91 intervention and standard care heterogeneous.

92

93

94

95

96

97

98

99

100

101

102

103

104

105

106

107

108

109

110 INTRODUCTION

111 Tobacco smoking remains one of the leading preventable causes of death and disease in England and
112 is responsible for an estimated 74,600 deaths annually [1, 2]. Although smoking prevalence in the UK
113 has steadily declined over the last few decades, rates remain at least 50% higher for people with
114 mental health conditions compared to those without [3]. With average smoking prevalence figures of
115 40%, people with mental illness are more than twice as likely to smoke compared to those without
116 [4]. Even higher smoking rates of up to 70% are seen in subgroups, such as hospitalised patients with
117 mental health conditions [4, 5]. This results in substantially increased risks of premature smoking-
118 related morbidity and mortality in this population [4]. Up to 20 life years are lost largely due to
119 diseases related to smoking and this is the biggest contributor to the health inequalities experienced
120 by people with mental illness [6].

121

122 Although people with mental health conditions are able [7] and more likely to be motivated [8] to
123 quit smoking than those without, mainstream stop-smoking services are not commonly accessed by
124 this population [9, 10] and are decreasingly resourced to support the needs of smokers with mental
125 illness for tailored support [11-13]. However, National Institute for Health and Care Excellence (NICE)
126 [14] guidance recommends that all mental health settings be entirely smokefree without exemption,
127 with no facilitated smoking breaks, and evidence-based tobacco dependence treatment for smoking
128 cessation, harm reduction and support for temporary abstinence available to all patients who smoke.

129

130 For many people with mental illness, a smokefree inpatient stay constitutes a rare or first experience
131 as an adult of sustained abstinence, near-abstinence, or substantial reduction of tobacco
132 consumption [15]. Evidence suggests individuals can successfully remain abstinent during their
133 smokefree inpatient stay when behavioural and/or pharmacological support is offered [15, 16].
134 However, while a smokefree stay may result in temporary abstinence from tobacco or cessation, the
135 risk of relapse post-discharge is high [17] with many individuals returning to smoking within a few
136 days [18]. A lack of support in the immediate post-discharge period and the resulting relapse or
137 return to heavy prehospital smoking patterns renders efforts and resources during the inpatient
138 episode inefficient, as positive smoking behaviour change achieved during the inpatient stay may be
139 lost. Therefore, it is vital to provide support post-discharge to prevent relapse.

140

141 The overall aim of the Promoting Smoking Cessation and Preventing Relapse to Tobacco use
142 following a smokefree mental health in-patient stay (SCEPTRE) study is to determine the feasibility
143 and acceptability of delivering the multi-component SCEPTRE intervention in National Health Service

144 (NHS) adult mental health services. A second objective is to describe the initial effect of this
145 intervention on participants' smoking-related outcomes. We will also carry out a process evaluation
146 and obtain feedback from all stakeholders relating to the research participation process and the
147 acceptability of the intervention and gain an understanding of the importance and potential impact
148 of individual intervention components. Finally, we will estimate the cost of delivering the SCEPTRE
149 intervention and the control condition and the feasibility of collecting health economic data.

150

151 **METHODS AND ANALYSIS**

152 The SCEPTRE feasibility trial protocol is reported in accordance with the guidelines presented in the
153 Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) checklist [19] and the
154 Template Intervention Description and Replication guidelines [20]. See supplemental appendix 1 for
155 SPIRIT checklist.

156

157 **Patient and public involvement (PPI)**

158 The SCEPTRE PPI group is integral to the trial and consists of six current/recent smokers with lived
159 experience of a mental health inpatient stay and their carers. Members have contributed to the
160 design of the intervention components, participant study documents, intervention resources, and
161 intervention delivery mechanisms and measures. The group meets quarterly to provide feedback on
162 study progress and have been kept up to date with frequent trial updates. Additionally, the
163 Programme Steering Committee (PSC) has an independent lay member representative. The results of
164 the study will be made available to trial participants, PPI panel members, participating NHS trusts
165 and the wider public through the trial website and other popular media.

166

167 **Trial design**

168 An individually randomised, controlled feasibility trial will be conducted with embedded qualitative
169 interviews and health economic component (see Consolidated Standards of Reporting Trials
170 (CONSORT) diagram in Fig. 1).

171

172 [insert figure 1]

173

174 **Study setting**

175 Participants will be recruited from up to eight English NHS mental health Trusts. To be eligible to
176 participate, trusts must be committed to, and working towards full implementation of smokefree
177 policy in line with national guidance [14].

178

179 **Participants**

180 To be eligible for inclusion in this study, participants must (1) be aged 18 years and older (no
181 maximum age); (2) be admitted to an acute adult mental health inpatient ward; (3) if detained under
182 the mental health act, be granted unescorted (Section 17) leave i.e. leave the ward without being
183 supervised (4) have discharge planned to an address/accommodation within the trust's catchment
184 area or a pre-defined radius agreed with participating trusts; (5) be a tobacco smoker at time of
185 admission or at any point after (as patients occasionally still commence smoking after admission) and
186 express an interest in maintaining abstinence if smokefree at time of assessment. Or express an
187 interest in positively changing their smoking behaviour following discharge (including reduction of
188 cigarette consumption; using e-cigarettes); (6) be able to understand and communicate in English; (7)
189 have access to a telephone or computer/alternative digital device to receive post-discharge support;
190 and (8) be willing and able to provide informed consent. Patients currently being treated within a
191 psychiatric intensive care unit (PICU) will not be recruited. Additionally, those deemed not suitable to
192 being approached to participate in the study (at clinician discretion) and those discharged to any
193 trust accommodation with a smokefree policy will be ineligible to participate.

194

195 **Participant recruitment and study procedures**

196 Patient identification and screening for eligibility

197 Participating trusts will identify, from electronic patient records, all patients who have been recorded
198 on or after admission as a current smoker. Trust-based researchers will also visit participating wards
199 and work with ward staff and other healthcare professionals to identify potential participants
200 meeting the inclusion criteria. Potentially eligible participants will be approached by a member of
201 the Trust research team to ascertain their interest in the study and seek permission to provide
202 further information about the research. Screened patients will be recorded, along with reasons for
203 ineligibility, non-approach and non-consent, in the eligibility screening log.

204

205 Ward staff will be encouraged to actively promote the study, for example, during ward community
206 meetings and interactions with patients (e.g., during pre-discharge assessments and discharge
207 planning). Patients who are identified as potential participants but who are too unwell to participate
208 will be frequently reviewed to allow participation in the study when their mental health allows.

209

210 Informed consent and data collection

211 Consent will be obtained in-person or remotely via telephone/video call. All participants will have
212 received a copy of the PIS at least 24 hours prior to obtaining consent. The consent form will also
213 contain optional statements in relation to consent to interview for the qualitative aspect of the study.
214

215 Once participant eligibility has been confirmed and consent obtained, participants will be asked to
216 complete a baseline questionnaire. If required, consent procedures and collection of baseline data
217 can be separated into two visits dependent on participant preference. Data will be collected either
218 using bespoke case report forms (CRFs) completed electronically via the secure web-based outcome
219 data collection interface 'REDCap', over the telephone with a SCEPTRE researcher, or collected on
220 paper CRFs returned via free post envelopes to York Trials Unit (YTU). All reporting of data collection
221 will be undertaken in line with the CONSORT statement [22]. The baseline assessment includes socio-
222 demographic information as well as information on mental and physical health and smoking history
223 and behaviour. Participants who self-report they have not smoked will be asked to provide an expired
224 air carbon monoxide (CO) reading. We will ask participants for full contact details at baseline
225 (including mobile phone number, email, and address), and any contact preferences.

226
227 After the baseline assessment is completed, a member of the trust's research team will randomise
228 participants to either the intervention or comparison group. All participants (intervention and
229 control) will be followed up for the purposes of the study via self-completed questionnaires at 3
230 months and 4-6 months post-randomisation to accommodate a variable second follow-up period
231 which allows us to extend the recruitment period without extending the duration of the study
232 overall. During the follow-up, outcome measures to be collected include smoking-related measures
233 and mental and physical health measures. While completing the follow-up questionnaires,
234 participants who self-report that they have not smoked in the previous seven days will be invited to
235 undertake a CO measurement to validate their abstinence from tobacco. Participants who decline
236 the invitation will be asked to provide a reason for declining, and this will be recorded on the
237 questionnaire.

238
239 At three months and the relevant follow up timepoints, a link to complete the relevant electronic
240 questionnaire on REDCap will be sent to participants via email, with the option to send a paper copy
241 to participants for postal completion or completion with a researcher over the phone or in person
242 instead as preferred. If participants select self-completion without a researcher and report
243 abstinence from tobacco use within the previous 7 days, then a researcher will contact the
244 participant to arrange a suitable time to obtain a CO reading in person to validate self-report. If no

245 response is received within one week, an automated reminder will be sent to the participant. If
246 participants do not respond following the automated reminder, a member of the research team will
247 contact the participant via their preferred contact preference to prompt completion. Participants will
248 receive shopping vouchers for completing the two follow-up assessments.

249

250 Qualitative interviews

251 Participants from both the control and intervention arms will be invited to take part in a short semi-
252 structured interview following the completion of the SCEPTRE trial to gain a more in-depth
253 understanding of the acceptability and feasibility of the study procedures. Interviews, guided by a
254 schedule of topics developed from the APEASE criteria will examine the intervention delivery
255 process, facilitators, and barriers of delivering the intervention, as well as the obtaining feedback
256 from intervention arm participants. This will allow for future refinement and improvement of the
257 intervention and research processes involved. Between nine and 12 patient participants in total (6-8
258 participants from the intervention arm; 3-4 participants from the control arm) will be interviewed.
259 Up to four informal caregivers that can include family and friends (but not exclusively) of participants
260 in the intervention arm will be invited to participate in short semi-structured interviews at 3-month
261 follow-up to obtain their views on the acceptability and feasibility of intervention delivery methods.
262 Semi-structured interviews will also be conducted with the leading mental health worker delivering
263 the intervention from each of the Trusts in the week following the completion of the final participant
264 in the intervention. Interviews will explore their experience and perceptions of delivering the
265 intervention and assess the fidelity of delivery. Up to six trust stakeholders will be invited to
266 participate in online focus group discussions (FGDs) to explore the experiences and perceptions of
267 trust-based stakeholders of supporting the conduct of the research.

268

269 **Randomisation and blinding**

270 Randomisation will be 1:1 to either the intervention or comparison arm, stratified by recruiting site
271 and using randomly permuted blocks of randomly varying sizes. The randomisation schedule will be
272 generated by a statistician at YTU not involved in the recruitment of participants and will be
273 implemented in the REDCap system to ensure allocation concealment. Following a baseline
274 assessment, randomisation will be undertaken by a member of the Trust's research team. Due to the
275 nature of the SCEPTRE intervention, the trust-based researchers and participants will not be blinded
276 to allocation. The trial statistician conducting the analyses will not be blinded. Following allocation to
277 a study arm, the researcher will receive an email with the participant's allocation attached. The
278 outcome of the allocation will be communicated to the participant where possible in person but may

279 also be communicated by text or telephone call. Those participants randomised to the intervention
280 arm will be contacted by the interventionist to arrange a time to complete the pre-discharge
281 assessment. Details of participants allocated to the control group will be provided to ward staff to
282 allow for the delivery of the usual tobacco dependency support offered by the trust. All participants’
283 GPs will be informed of their allocation by letter. A copy of the GP letter will also be held in the Trust
284 electronic notes, so Community Mental Health Teams (CMHTs) are aware of patients’ participation in
285 the study.

286

287 **Intervention**

288 Control arm: usual care

289 Participants randomised to the control arm will receive usual care. The local offer of smoking
290 cessation support is variable across NHS mental health trusts. Usual care in some trusts may be
291 comprehensive and include behavioural and pharmacological support during admission, whereas
292 others may provide limited support (e.g., access to nicotine replacement therapy). Detailed
293 information on what usual care entails on each inpatient ward will be collected. All participants will
294 be provided with information of how to access Stop Smoking Services post-discharge.

295

296 Intervention arm: SCEPTRE intervention package

297 Participants assigned to the intervention group will receive a 12-week intervention consisting of
298 components aimed at promoting or maintaining smoking-related behaviour change among patients
299 following discharge from a smoke-free mental health inpatient setting. See Fig. 2 for the SCEPTRE
300 intervention pathway. The intervention development process was guided by the Behaviour Change
301 Wheel model [23] and theoretically underpinned by the Theoretical Domains Framework [24] and
302 the Behavioural Change Technique taxonomy [25]. Intervention components were identified and
303 further developed based on two systematic reviews and a Delphi-style consultation process with key
304 stakeholders, including clinicians and patients [16, 21, 26]. To ensure fit within the context of mental
305 health services, refinement of the draft intervention was undertaken in collaboration with clinicians
306 and experts in the field of tobacco control, and members of the SCEPTRE PPI panel. A more detailed
307 description of the intervention and its development is provided elsewhere [21]. The intervention will
308 be delivered by trained mental health workers, named ‘My-Try Specialists’ (MTSs). The manualised
309 intervention consists of several core and additional components outlined in Table 1.

310

311

312

313

314

Table 1. Summary of individual SCEPTRE intervention components

Intervention component	Core/ additional	Aim	Frequency	Delivery
Pre-discharge reflection, evaluation and goal setting sessions	Core	Provide personalised and tailored support to assist participants in identifying and planning their smoking-related behaviour change goals. Discussions will also determine if participants want to use additional intervention components.	Participant-led; may include up to two sessions lasting up to 45 minutes	MTS to deliver
Provision of a bespoke and personalised resource folder: My-Try kit	Core	Kit including practical information and motivational content to support participants following discharge.	One kit provided pre-discharge	MTS to provide kit
Nicotine Replacement Therapy (NRT)/e-cigarette selection and advice	Core	To discuss preferences for NRT or e-cigarette support as well as practical advice in relation to using the products and obtaining a longer-term supply.	Discussed during pre-discharge reflection and evaluation session, and MTS will continue to provide advice in behavioural support calls	MTS to deliver
Tailored behavioural support calls (via telephone or video call)	Core	Provide personalised and tailored support, assist the participant in maintaining positive change achieved during their smokefree admission and achieving their behaviour change goals, and provide feedback and encouragement on participant's progress.	Calls lasting 10-30 minutes for 12-weeks. On the first five days post-discharge, calls will be made daily, and weekly thereafter for the remaining eleven weeks	MTS to deliver
Smoke Free app	Additional	Provide additional support to participants, including its offer of 24/7 live smoking cessation advisor support	As required	MTS to deliver 'onboarding' session; smoking cessation advisors to provide advice via app
Text-based support	Additional	Personalised text messages to provide practical and motivational information to participants based on their	15-30 text messages for 8-15 days dependent on	MTS to deliver

	individual goals (Appendix 2 shows example text messages)	goals
315		
316	[insert Fig. 2]	
317		
318	Interventionist training, supervision and competency	
319	The MTS role aims to provide patients with tailored behavioural and social support and information	
320	to enable the continued change in smoking behaviours following discharge from a smoke-free mental	
321	health ward. To fulfil the MTS role, prospective interventionists are required to have knowledge of	
322	evidence-based methods in the treatment of tobacco dependency, including completion of the	
323	National Centre for Smoking Cessation Training (NCSCT) Practitioner Training module and the	
324	speciality course on smoking cessation and mental health. A bespoke training session designed to	
325	address the practicalities of smoking behaviour change in people with mental illness, and which	
326	covers e-cigarette use and interactions between tobacco smoke and certain antipsychotic	
327	medications (e.g., clozapine) in line with Royal College of Psychiatrists guidance, [27, 28] will be	
328	delivered.	
329		
330	MTSs will undertake self-guided online training supplemented with an in-person training session on	
331	the delivery of the manualised SCEPTRE intervention facilitated by members of the core SCEPTRE	
332	research team. Both clinical supervision, provided by the TRUST PI or nominated individual and	
333	procedural supervision, provided by members of the core SCEPTRE research team, on a fortnightly	
334	basis will be provided throughout the interventional period of the study. Fidelity of intervention	
335	delivery will be optimised through monthly supervision sessions and monitored using self-	
336	assessment checklists and logs for MTSs delivering the intervention. The log will allow MTSs to	
337	record all contacts with participants, and the research team will judge the degree to which the	
338	intervention as designed has been delivered in practice. Additional random fidelity checks will be	
339	carried out.	
340		
341	Outcome measures and progression criteria	
342	The schedule of data collection is shown in (Fig. 3) the SPIRIT Figure.	
343		
344	[insert Fig. 3]	
345		
346	Primary feasibility outcomes	

347 The primary outcome of this feasibility trial will be to assess whether prespecified progression
 348 criteria are met to progress to the full randomised trial of the SCEPTRE intervention. Progression
 349 criteria are based on participant recruitment, retention, number of trusts enrolled and the feasibility
 350 of collecting carbon monoxide readings (Table 2).

351

352

353 **Table 2. SCEPTRE feasibility study progression criteria**

Progression criterion	Target at end of internal pilot	Green (Progression to full RCT without major modifications)	Amber (Progression to full RCT may be possible with modifications)	Red (Full RCT not feasible)
Participant recruitment	64 Participants recruited	100% (64)	60-99% (38-64)	<60% (<38)
Participant retention (Primary outcome data available at 6 months)	At least 80%	80-100% (51-64)	60-80% (38-51)	<60% (<38)
Trusts enrolled Each Trust expected to provide 1-2 sites/wards (can be more)	8	80-100% (6-8)	60-80% (5-6)	<60% (<5)
Feasibility of collecting carbon monoxide reading (biochemically validated primary outcome measure)	CO reading collected for at least 75% of all participants (intervention and control group) reporting to be abstinent	75-100% (absolute figures to be confirmed)	50-75%	<50

354

355 **Proposed trial outcome measures**

356 All participants will be asked to complete follow-up questionnaires with a member of the research
 357 team at 3- and either 4-, 5-, or 6-months post-randomisation (see Fig. 3).

358

359 Smoking-related measures: Smoking status; 7-day point prevalence abstinence validated by exhaled
 360 CO <10ppm, self-reported relapse following discharge from hospital, continuous abstinence, quit
 361 attempts, nicotine dependence as assessed by the Heaviness of Smoking Index (HSI) [30], strength of
 362 urges to smoke [31], level of motivation to quit as assessed by the Motivation to Stop Smoking

363 Questionnaire [32] to assess how motivation changes over time and affects cessation outcomes, self-
364 efficacy related to smoking cessation and use of e-cigarettes and NRT since discharge.

365

366 Mental and physical health measures: The nine-item Patient Health Questionnaire depression scale
367 (PHQ-9) [33], the Generalised Anxiety Disorder 7-item scale (GAD-7) [34], and the quality-of-life scale
368 (EQ-5D) [35], will be included. Frequency of use of health services (health economic data) since
369 discharge will also be collected.

370

371 We will review the suitability and definitions of the two core smoking-related outcome measures, as
372 per current debate in the field [36], as follows: for 7-day point prevalence abstinence, we will review
373 and potentially adjust downward the CO threshold of <10 ppm for biochemical validation, depending
374 on suitability of this approach for our patient population; for the multiple continuous abstinence
375 outcome measures (1 – 6 months), we will review availability and congruency of data and define one
376 consistent secondary outcome measure accordingly.

377

378 **Sample size considerations**

379 The feasibility study will be conducted across approximately 12 acute adult mental health inpatient
380 wards of the participating eight Trusts. Based on combined monthly discharge figures of ~200
381 patients, of which we estimate conservatively that ~140 will be eligible to participate, a smoking
382 prevalence of ~60%, and a conservative estimate of willingness of smokers to take part of 20%, we
383 will aim to recruit a minimum of 64 patients, who will be individually randomised, at a 1:1 ratio, to
384 the SCEPTRE intervention or the control arm. A trial of this size [37] will also allow a participation
385 rate of 15% and completion rate of 80% to be estimated within a 95% confidence interval of $\pm 3\%$ and
386 $\pm 10\%$ respectively [38].

387

388 **Additional qualitative and quantitative measures of feasibility and acceptability**

389 In line with recommendations for the reporting of protocols of pilot and feasibility trials [29], a range
390 of quantitative and qualitative data for all participants (intervention and control arm) determining
391 the acceptability and feasibility of intervention delivery and research procedures will be collected.

392

393 Recruitment and retention

394 All participants screened will be recorded in the eligibility screening log, with reasons for ineligibility
395 and approach outcomes (outlined above). Retention rates will be monitored throughout the duration
396 of the study and the flow of participants will be detailed in a CONSORT diagram.

397

398 Compliance with the protocol

399 In addition to the interviews with MTSs (see above), compliance to the protocol and fidelity of
400 intervention delivery will be optimised through monthly supervision sessions and monitored using
401 self-assessment checklists and logs for MTSs delivering the intervention. The log will allow MTSs to
402 record all contacts with participants, and the research team will judge the degree to which the
403 intervention as designed has been delivered in practice. Any deviations from the protocol will be
404 reported to YTU using a protocol deviation log.

405

406 Level of contamination and suitability of randomisation approach

407 The suitability of the individual randomisation approach will be assessed by using qualitative and
408 quantitative data of control group participants who quit or reduced smoking at 3- and 4, 5, or 6-
409 months post-randomisation. Quantitative investigation will take place in the context of follow-up, to
410 identify and specify smoking behaviour change. Qualitative data will be obtained via interviews
411 (outlined above) to investigate reasons for smoking behaviour change and identify potential
412 (unintentional) links with the SCEPTRE intervention. Based on our findings, we will estimate the
413 presence/extent of contamination in the control group, and the need to change the unit of
414 randomisation to clusters. If more than 30% of control participants appear to have changed aspects
415 of their smoking behaviour due to factors directly related to our intervention, we will consider
416 strategies to reduce contamination in the full RCT, including the possibility of designing the full RCT
417 as a cluster trial, with wards as the unit of randomisation.

418

419 **Data management**

420 Each site will hold data according to the General Data Protection Regulations (GDPR) and the Data
421 Protection Act 2018. All data will be stored on a secure password-protected server and archived for
422 10 years after study completion. Patients will be assigned a unique trial number and this will be used
423 on CRFs; patients will not be identified by their name in order to maintain confidentiality.

424

425 **Data analysis**

426 A statistical analysis plan (SAP) giving details of the planned analyses will be drafted before data
427 collection has been completed and reviewed by the Programme Management Group (PMG) and PSC.
428 A brief description of the planned analyses is given below.

429

430 The statistical analysis will be carried out by a statistician based in YTU, using Stata v17 or later. The
431 reporting of this trial will follow CONSORT guidelines for pilot and feasibility trials [22]. A flow
432 diagram will be produced, depicting the flow of patients through the trial. The number of patients
433 screened, eligible, consenting, and randomised will be summarised, with reasons for ineligibility and
434 non-consent given where available. Baseline data will be summarised descriptively by randomised
435 group, with no formal statistical comparisons being undertaken [39]. Continuous variables will be
436 summarised using descriptive statistics, while categorical variables will be summarised using counts
437 and percentages. Descriptive statistics will summarise participant outcomes by randomised group
438 and timepoint, including the amount of missing data. Relevant measures of recruitment and
439 retention will be calculated and compared against the pilot progression criteria. The recruitment rate
440 will be estimated and presented alongside a corresponding 95% confidence interval. Measures of
441 contamination and participant engagement with the multiple components of the intervention will be
442 summarised descriptively.

443

444 Health economic analysis will be conducted as a preparatory step towards a comprehensive
445 economic evaluation in the subsequent definitive RCT. Costs associated with the delivery of the
446 SCEPTRE intervention and usual care will be estimated. All resources used in the provision of the
447 intervention, such as the training for the MTSs, the staff time spent on delivering the intervention,
448 and the NRT and e-cigarettes dispensed, will be recorded alongside the trial. Data on the resources
449 used in usual care through self-completed questionnaires at 3- and either 4-, 5-, or 6-months post-
450 randomisation will be collected. A micro-costing approach, collecting detailed information about
451 health service use, will be applied to generate estimated intervention costs for both arms by
452 multiplying the quantity of each identified resource by its corresponding unit cost. We will pilot the
453 data collection tools used to gather health economics data. We will test the feasibility and
454 acceptability of the health service use questionnaire and the outcome measure instrument (i.e., the
455 EQ-5D-5L questionnaire). We will examine the completion rates, identify any challenges or barriers to
456 completion, and make necessary modifications to the questionnaires for use in the full trial. The
457 methods and findings will be summarised in a report that can be used to inform the design and
458 conduct of the economic evaluation in the full trial stage.

459

460 Qualitative data analysis will be undertaken by group, e.g., participants, MTSs, friends/family, Trust
461 stakeholders. Data will be analysed using NVivo software (QSR International Pty Ltd, Melbourne,
462 Australia). First, an inductive approach using thematic analysis will be used to identify nodes and
463 sub-themes in the data [40]. Transcripts will be coded line by line by two researchers, with

464 preliminary code names assigned to the data items and iteratively developed. Preliminary codes will
465 be checked and discussed with a third researcher, experienced in qualitative research and the
466 behaviour change wheel. Following this, a deductive approach will be used to chart sub-themes to
467 the APEASE (Acceptability, Practicability, Effectiveness, Affordability, Side-effects, and Equity) criteria.
468 The data will be presented and discussed in a wider research team meeting to refine and confirm the
469 final interpretation.

470

471 **Trial management**

472 A Programme Management Group (PMG) has been established to oversee the day-to-day
473 management (e.g., protocol and ethics approvals, set-up, recruitment, data collection, data
474 management) of the study, and is chaired by the Chief Investigator (CI). Membership includes co-CIs,
475 co-investigators, research staff on the project and PPI representation. The role of the PMG is to
476 monitor all aspects of the conduct and progress of the trial, ensure that the protocol is adhered to
477 and take appropriate action to safeguard participants and the quality of the trial itself. Throughout
478 the project there will be regular videoconference contact supplemented by face-to-face meetings
479 where required. Frequency of meetings will vary depending on the stage of the trial. The PMG,
480 through the York Trials Unit (YTU), will provide feedback on trial progress to the Programme Steering
481 Committee (PSC) established to provide overall independent oversight for SCEPTRE on behalf of the
482 Sponsor and Project Funder and to ensure that the project is conducted to the rigorous standards set
483 out in the Department of Health's Research Governance Framework for Health and Social Care and
484 the Guidelines for Good Clinical Practice (GCP). Furthermore, the PMG through the YTU, will provide
485 feedback to the Data Monitoring and Ethics Committee (DMEC) established to monitor safety and
486 efficacy data as well as quality and compliance data and ensure that the protocol is accurately
487 followed, and the study is GCP compliant.

488

489 **Ethics**

490 The protocol (Version 1.0_05.09.2023) for this study and the informed consent form (see online
491 supplemental appendix 2) were approved by the North West - Greater Manchester West Research
492 Ethics Committee (REC) (23/NW/0312). The Investigators will ensure that this study is conducted in
493 full conformity with current regulations, the current revision of the Declaration of Helsinki, and with
494 the principles of GCP. We will adhere to the UK Framework for Health and Social Care Research [22,
495 39]. The programme manager/CI will obtain approval for all amendments.

496

497 **Adverse events**

498 All adverse events (AEs) occurring during the study observed by the investigator or reported by MTSs
499 or participants, will be recorded on the SCEPTRE Adverse Event Form for return to YTU. All serious
500 adverse events (SAEs) will be entered onto the SAE reporting form and sent via REDCap or encrypted
501 email to YTU within 24 hours of the investigator becoming aware of the event. Once received,
502 causality and expectedness will be confirmed by the CI or a medical co-applicant or PSC member not
503 acting as a site Principal Investigator (PI). Any change of condition or other follow-up information
504 should be sent as soon as it is available or at least within 24 hours of the information becoming
505 available. Events will be followed up until the event has resolved or a final outcome has been
506 reached. SAEs that are deemed to be unexpected and related to the trial will be notified to the REC
507 and sponsor within 15 days by YTU. All such events will be reported to the PSC and DMEC at their
508 next meetings. Protocols and SOPs have been developed to identify and manage risks of suicide and
509 harm to participants.

510

511 **Dissemination**

512 We will share results widely through local, national and international academic, clinical and PPI
513 networks. The results will be disseminated through conference presentations, peer reviewed journals
514 and will be published on the trial website: <https://sceptresearch.com/>.

515

516 **Trial status**

517 This protocol (V.1.0) was approved on 6th November 2023. Recruitment to the SCEPTRE feasibility
518 study opened on 23 January 2024 with the first participant randomised on 13th February 2024. The
519 trial is ongoing. Reporting of the trial is anticipated in the first quarter of 2025.

520

521 **DISCUSSION**

522 In line with NICE recommendations, that mental health settings become entirely smokefree, and that
523 mental health patients should have access to evidence-based stop smoking treatment [14], SCEPTRE
524 aims to test ways to support mental health inpatients after discharge in maintaining or achieving
525 abstinence from tobacco smoking. At present, no evidence-based strategies to help maintain or
526 achieve a smokefree lifestyle and avoid relapse after discharge exist. As such, SCEPTRE feasibility
527 study will inform the design of a future large-scale randomised controlled trial. This large-scale trial
528 will aim to test the effectiveness and cost-effectiveness of a complex intervention to promote or
529 maintain smoking-related behaviour change among patients following discharge from a smoke-free
530 mental health inpatient setting. One limitation of this study is the potential for contamination in the
531 control group. However, we will assess and estimate the presence/extent of this, and the need to

532 change the unit of randomisation to clusters. Secondly, this is a multi-component intervention which
533 makes it difficult to delineate impact very clearly. The process evaluation will aim to provide insights
534 on the importance of individual intervention components. The study is focused on acute adult
535 mental health departments making generalisation beyond this setting difficult. Usual care is
536 heterogeneous and policy/practice landscapes are shifting rapidly. We will collect information on
537 what usual care entails on each inpatient ward.

538

539 If effective and implemented in NHS mental health settings, the SCEPTRE intervention will directly
540 benefit patients (and their families) and has the potential to save lives and NHS resources, and to
541 decrease health inequalities that exists for people with mental health conditions.

542

543 **Acknowledgements**

544 We wish to thank the SCEPTRE PPI Panel for their assistance in the development of
545 patient/participant processes and materials. We also acknowledge the valuable contributions of the
546 NCSCCT for their assistance in the development and delivery of MTS training on smoking and mental
547 health, and the Smoke Free App team for their contributions to the development of processes and
548 materials to support participant engagement with the Smoke Free App.

549

550 **Authors' Contributions**

551 ER conceived the idea for the study. ER, LH, ES, LC, ML, and CP led the development of the
552 intervention. VE is the Trial Co-ordinator and SB and LSinclair are the trial managers. AM and FW are
553 the study statisticians. GR, SG, CH, TC, JW, SP, PC, MH, JB, ML, CP, PG, LShahab, LC and MH are co-
554 applicants and SH is the independent PPI co-applicant. JB, PC, TC, PG, SG, CH, SP, LShahab, and JW
555 provide academic expertise. PPW drafted the manuscript. All authors contributed to protocol writing
556 and approved the final version.

557

558 **Funding statement**

559 The SCEPTRE Feasibility Trial is funded by Programme Grants for Applied Research (NIHR200607).
560 The sponsor is the Sheffield Health and Social Care NHS Foundation Trust. Catherine Hewitt, Simon
561 Gilbody and Tim Coleman are NIHR Senior Investigators. The trial will be monitored and audited in
562 accordance with the sponsor's procedures. The sponsor will play no role in the study design;
563 collection, management, analysis, and interpretation of data; writing of the report; and the decision
564 to submit the report for publication. PPW, LH, ES, and ER are supported by the NIHR Yorkshire and
565 Humber Applied Research Collaboration.

566

567 **Competing interest statement**

568 LS has received honoraria for talks, an unrestricted research grant and travel expenses to attend
569 meetings and workshops from Pfizer and an honorarium to sit on advisory panel from Johnson &
570 Johnson, both pharmaceutical companies that make smoking cessation products. He has acted as
571 paid reviewer for grant awarding bodies and as a paid consultant for health care companies. Other
572 research has been funded by the Department of Health, UKRI, a community-interested company
573 (National Centre for Smoking Cessation) and charitable sources (Cancer Research UK, Yorkshire
574 Cancer Research). He has never received personal fees or research funding of any kind from alcohol,
575 electronic cigarette or tobacco companies. All other authors declare no conflicts of interest.

576

577

578

579

580

581

582

583

584

585

586

587

588

589

590

591

592

593

594

595

596

597

598

599

600

601

602

603

604

605

606

607 **REFERENCES**

- 608 1. Digital, N. *Statistics on Smoking, England 2020*. 2020 [cited 2023 08/08]; Available from:
609 [https://digital.nhs.uk/data-and-information/publications/statistical/statistics-on-](https://digital.nhs.uk/data-and-information/publications/statistical/statistics-on-smoking/statistics-on-smoking-england-2020/part-1-smoking-related-ill-health-and-mortality)
610 [smoking/statistics-on-smoking-england-2020/part-1-smoking-related-ill-health-and-](https://digital.nhs.uk/data-and-information/publications/statistical/statistics-on-smoking/statistics-on-smoking-england-2020/part-1-smoking-related-ill-health-and-mortality)
611 [mortality](https://digital.nhs.uk/data-and-information/publications/statistical/statistics-on-smoking/statistics-on-smoking-england-2020/part-1-smoking-related-ill-health-and-mortality).
- 612 2. Digital, N., *Statistics on Smoking, England - 2016* 2016.
- 613 3. Richardson, S., A. McNeill, and L.S. Brose, *Smoking and quitting behaviours by mental health*
614 *conditions in Great Britain (1993–2014)*. Addictive behaviors, 2019. **90**: p. 14-19.
- 615 4. Psychiatrists, R.C.o.P.R.C.o., *Smoking and mental health*. 2013: London.
- 616 5. Meltzer, H., et al., *The prevalence of psychiatric morbidity among adults living in institutions*.
617 *International Review of Psychiatry*, 2003. **15**(1-2): p. 129-133.
- 618 6. Cheeseman H, H.H., *The stolen years: The mental health and smoking action report* 2016:
619 London.
- 620 7. Peckham, E., et al., *Smoking cessation in severe mental ill health: what works? An updated*
621 *systematic review and meta-analysis*. BMC psychiatry, 2017. **17**(1): p. 1-18.
- 622 8. Brose, L.S., et al., *Mental health, smoking, harm reduction and quit attempts – a population*
623 *survey in England*. BMC Public Health, 2020. **20**(1): p. 1237.
- 624 9. McNally, L. and E. Ratschen, *The delivery of stop smoking support to people with mental*
625 *health conditions: a survey of NHS stop smoking services*. BMC Health Services Research,
626 2010. **10**: p. 1-5.
- 627 10. McNally, L., C. Todd, and E. Ratschen, *The prevalence of mental health problems among users*
628 *of NHS stop smoking services: effects of implementing a routine screening procedure*. BMC
629 *health services research*, 2011. **11**(1): p. 1-4.
- 630 11. Knowles, S., et al., *Making the journey with me: a qualitative study of experiences of a*
631 *bespoke mental health smoking cessation intervention for service users with serious mental*
632 *illness*. BMC psychiatry, 2016. **16**: p. 1-9.
- 633 12. Peckham, E., et al., *Smoking Cessation Intervention for severe Mental Ill Health Trial*
634 *(SCIMITAR): a pilot randomised control trial of the clinical effectiveness and cost-effectiveness*
635 *of a bespoke smoking cessation service*. Health Technology Assessment (Winchester,
636 England), 2015. **19**(25): p. 1-148, v.
- 637 13. Parker, C., A. McNeill, and E. Ratschen, *Tailored tobacco dependence support for mental*
638 *health patients: a model for inpatient and community services*. Addiction, 2012. **107**: p. 18-
639 25.
- 640 14. NICE. *Tobacco: preventing uptake, promoting quitting and treating dependence [NG209]*.
641 2021; Available from: <https://www.nice.org.uk/guidance/ng209>.
- 642 15. Brose, L.S., E. Simonavicius, and A. McNeill, *Maintaining abstinence from smoking after a*
643 *period of enforced abstinence—systematic review, meta-analysis and analysis of behaviour*
644 *change techniques with a focus on mental health*. Psychological medicine, 2018. **48**(4): p.
645 669-678.

- 646 16. Shoemith, E., et al., *Supporting smoking cessation and preventing relapse following a stay in*
647 *a smoke-free setting: a meta-analysis and investigation of effective behaviour change*
648 *techniques*. *Addiction*, 2021. **116**(11): p. 2978-2994.
- 649 17. Prochaska, J.J., et al., *Return to smoking following a smoke-free psychiatric hospitalization*.
650 *American Journal on Addictions*, 2006. **15**(1): p. 15-22.
- 651 18. Mussulman, L.M., et al., *Rapid relapse to smoking following hospital discharge*. *Preventive*
652 *medicine reports*, 2019. **15**: p. 100891.
- 653 19. Chan, A.W., et al., *SPIRIT 2013 statement: defining standard protocol items for clinical trials*.
654 *Ann Intern Med*, 2013. **158**(3): p. 200-7.
- 655 20. Alvarez, G., F. Cerritelli, and G. Urrutia, *Using the template for intervention description and*
656 *replication (TIDieR) as a tool for improving the design and reporting of manual therapy*
657 *interventions*. *Man Ther*, 2016. **24**: p. 85-9.
- 658 21. Shoemith, E., et al., *Promoting and Maintaining Changes in Smoking Behavior for Patients*
659 *Following Discharge from a Smoke-free Mental Health Inpatient Stay: Development of a*
660 *Complex Intervention Using the Behavior Change Wheel*. *Nicotine and Tobacco Research*,
661 2023. **25**(4): p. 729-737.
- 662 22. Eldridge, S.M., et al., *CONSORT 2010 statement: extension to randomised pilot and feasibility*
663 *trials*. *bmj*, 2016. **355**.
- 664 23. Michie, S., L. Atkins, and R. West, *The behaviour change wheel*. A guide to designing
665 interventions. 1st ed. Great Britain: Silverback Publishing, 2014. **1003**: p. 1010.
- 666 24. Cane, J., D. O'Connor, and S. Michie, *Validation of the theoretical domains framework for use*
667 *in behaviour change and implementation research*. *Implementation science*, 2012. **7**: p. 1-17.
- 668 25. Michie, S., et al., *The behavior change technique taxonomy (v1) of 93 hierarchically clustered*
669 *techniques: building an international consensus for the reporting of behavior change*
670 *interventions*. *Annals of behavioral medicine*, 2013. **46**(1): p. 81-95.
- 671 26. Huddleston, L., et al., *A systematic review of mental health professionals, patients, and*
672 *carers' perceived barriers and enablers to supporting smoking cessation in mental health*
673 *settings*. *Nicotine and Tobacco Research*, 2022. **24**(7): p. 945-954.
- 674 27. Physicians, R.C.o. and R.C.o. Psychiatrists. *Smoking and mental health 2013* [cited 2022 23
675 November]; Available from: [https://www.rcplondon.ac.uk/projects/outputs/smoking-](https://www.rcplondon.ac.uk/projects/outputs/smoking-andmental-health)
676 [andmental-health](https://www.rcplondon.ac.uk/projects/outputs/smoking-andmental-health)
- 677 28. Royal College of Psychiatrists, *The prescribing of varenline and vaping (eletronic cigarettes)*
678 *to patients with severe mental illness. Position Statement (PS05/18)*. 2018.
- 679 29. Thabane, L. and G. Lancaster, *A guide to the reporting of protocols of pilot and feasibility*
680 *trials*. *Pilot and Feasibility Studies*, 2019. **5**(1): p. 37.
- 681 30. Borland, R., et al., *The reliability and predictive validity of the Heaviness of Smoking Index*
682 *and its two components: findings from the International Tobacco Control Four Country study*.
683 *Nicotine & Tobacco Research*, 2010. **12**(suppl_1): p. S45-S50.
- 684 31. Fidler, J.A., L. Shahab, and R. West, *Strength of urges to smoke as a measure of severity of*
685 *cigarette dependence: comparison with the Fagerström Test for Nicotine Dependence and its*
686 *components*. *Addiction*, 2011. **106**(3): p. 631-638.
- 687 32. (NCSCT), N.C.f.S.C.a.T. *Motivation to Stop Smoking* Available from:
688 <https://www.ncsct.co.uk/usr/pub/Motivation%20to%20stop%20smoking.pdf>.
- 689 33. Kroenke, K., R.L. Spitzer, and J.B. Williams, *The PHQ-9: validity of a brief depression severity*
690 *measure*. *Journal of general internal medicine*, 2001. **16**(9): p. 606-613.
- 691 34. Spitzer, R.L., et al., *A brief measure for assessing generalized anxiety disorder: the GAD-7*.
692 *Archives of internal medicine*, 2006. **166**(10): p. 1092-1097.
- 693 35. Byford, S., *The validity and responsiveness of the EQ-5D measure of health-related quality of*
694 *life in an adolescent population with persistent major depression*. *Journal of mental health*,
695 2013. **22**(2): p. 101-110.

- 696 36. Benowitz, N.L., et al., *Biochemical Verification of Tobacco Use and Abstinence: 2019 Update*.
697 Nicotine Tob Res, 2020. **22**(7): p. 1086-1097.
- 698 37. Metse, A.P., et al., *Efficacy of a universal smoking cessation intervention initiated in inpatient*
699 *psychiatry and continued post-discharge: A randomised controlled trial*. Australian & New
700 Zealand Journal of Psychiatry, 2017. **51**(4): p. 366-381.
- 701 38. Hertzog, M.A., *Considerations in determining sample size for pilot studies*. Research in
702 nursing & health, 2008. **31**(2): p. 180-191.
- 703 39. Senn, S., *Testing for baseline balance in clinical trials*. Statistics in medicine, 1994. **13**(17): p.
704 1715-1726.
- 705 40. Braun, V. and V. Clarke, *Thematic analysis*. 2012: American Psychological Association.
- 706